Lerner Jonathan, Goldfarb Melanie
University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Endocrine Tumor Program, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA.
Ann Surg Oncol. 2015 Dec;22(13):4187-92. doi: 10.1245/s10434-015-4546-8. Epub 2015 Apr 9.
Thyroid microcarcinomas (TMCs) are increasing in the general population, most commonly in older individuals; however, the incidence, characteristics, and outcomes of TMCs in pediatric patients has not been studied.
All patients ≤19 years of age with differentiated thyroid carcinoma (DTC) were identified from the surveillance, epidemiology, and end results registry from 1988 to 2009. Patients were divided into two groups based on tumor siz e: TMCs (≤1 cm) and tumors >1 cm. Demographic, tumor, and treatment characteristics, as well as overall survival (OS) and disease-specific survival (DSS), were compared between the two groups. The TMC group was analyzed separately for predictors of overall and disease-specific death.
Of 1825 pediatric DTC patients, 8.4 % had a TMC, and, over the past decade, the incidence has decreased (6.5 vs 14.5 %; p < 0.001). Compared to patients with DTCs >1 cm, TMCs were more likely to have papillary histology, negative lymph nodes, be treated with a partial thyroidectomy [odds ratio (OR) 3.46, CI 2.02-5.93] and not receive radioiodine (OR 1.77, CI 1.10-2.83). Neither OS (TMC: 253.59 months; DTC >1 cm: 257.97 months) nor DSS (TMC: 256.38 months; DTC >1 cm: 260.77 months) differed between groups. Predictors of decreased OS in the entire cohort included secondary malignancy status (p = 0.001), black race (p = 0.006) and follicular or Hurthle histology (p = 0.001). In patients with primary TMC, only follicular or Hurthle histology (p = 0.001) predicted decreased OS.
TMCs in patients ≤19 years of age are declining and comprise <10 % of pediatric thyroid malignancies. TMCs are most commonly treated with a partial thyroidectomy not followed by radioiodine, and have an excellent OS and DSS.
甲状腺微小癌(TMC)在普通人群中的发病率呈上升趋势,在老年人中最为常见;然而,儿科患者中TMC的发病率、特征和预后尚未得到研究。
从1988年至2009年的监测、流行病学和最终结果登记处中识别出所有年龄≤19岁的分化型甲状腺癌(DTC)患者。根据肿瘤大小将患者分为两组:TMC(≤1 cm)和肿瘤>1 cm。比较两组患者的人口统计学、肿瘤和治疗特征,以及总生存期(OS)和疾病特异性生存期(DSS)。对TMC组分别分析总死亡和疾病特异性死亡的预测因素。
在1825例儿科DTC患者中,8.4%患有TMC,在过去十年中,发病率有所下降(6.5%对14.5%;p<0.001)。与肿瘤>1 cm的DTC患者相比,TMC更可能具有乳头状组织学、阴性淋巴结,接受甲状腺部分切除术治疗[比值比(OR)3.46,可信区间(CI)2.02 - 5.93],且不接受放射性碘治疗(OR 1.77,CI 1.10 - 2.83)。两组之间的OS(TMC:253.59个月;DTC>1 cm:257.97个月)和DSS(TMC:256.38个月;DTC>1 cm:260.77个月)均无差异。整个队列中OS降低的预测因素包括继发性恶性肿瘤状态(p = 0.001)、黑人种族(p = 0.006)和滤泡性或许特莱组织学(p = 0.001)。在原发性TMC患者中,只有滤泡性或许特莱组织学(p = 0.001)可预测OS降低。
19岁及以下患者中的TMC发病率正在下降,占儿科甲状腺恶性肿瘤的比例不到10%。TMC最常采用甲状腺部分切除术治疗,术后不进行放射性碘治疗,并且具有良好的OS和DSS。